Bank of America
STRO icon

Bank of America’s Sutro Biopharma STRO Stock Holding History

Bank of America’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$470K Buy
18,873
+14,661
+348% +$265K ﹤0.01% 4933
2025
Q4 		$48.7K Sell
4,212
-7,731
-65% -$73.4K ﹤0.01% 5852
2025
Q3 		$104K Buy
11,943
+4,048
+51% +$34.4K ﹤0.01% 6577
2025
Q2 		$56.3K Sell
7,895
-3,015
-28% -$24.7K ﹤0.01% 6773
2025
Q1 		$70.9K Buy
10,910
+284
+3% +$4.47K ﹤0.01% 6638
2024
Q4 		$196K Sell
10,626
-2,289
-18% -$69.9K ﹤0.01% 6133
2024
Q3 		$447K Buy
12,915
+3,366
+35% +$132K ﹤0.01% 5561
2024
Q2 		$280K Buy
9,549
+3,809
+66% +$151K ﹤0.01% 5707
2024
Q1 		$324K Sell
5,740
-5,369
-48% -$237K ﹤0.01% 5609
2023
Q4 		$477K Buy
11,109
+2,110
+23% +$67K ﹤0.01% 5532
2023
Q3 		$312K Buy
8,999
+2,180
+32% +$95K ﹤0.01% 5641
2023
Q2 		$317K Sell
6,819
-24,711
-78% -$1.23M ﹤0.01% 5551
2023
Q1 		$1.46M Buy
31,530
+16,971
+117% +$1.08M ﹤0.01% 4623
2022
Q4 		$1.18M Buy
14,559
+10,188
+233% +$708K ﹤0.01% 4707
2022
Q3 		$242K Buy
4,371
+2,254
+106% +$133K ﹤0.01% 5869
2022
Q2 		$110K Sell
2,117
-24,607
-92% -$1.37M ﹤0.01% 6424
2022
Q1 		$2.2M Buy
26,724
+15,081
+130% +$1.44M ﹤0.01% 4493
2021
Q4 		$1.73M Buy
11,643
+8,022
+222% +$1.44M ﹤0.01% 4705
2021
Q3 		$684K Buy
3,621
+127
+4% +$24.1K ﹤0.01% 5397
2021
Q2 		$649K Buy
3,494
+1,100
+46% +$215K ﹤0.01% 5227
2021
Q1 		$545K Buy
2,394
+1,998
+505% +$474K ﹤0.01% 5286
2020
Q4 		$86K Sell
396
-2,894
-88% -$479K ﹤0.01% 6062
2020
Q3 		$330K Buy
3,290
+809
+33% +$76.4K ﹤0.01% 4996
2020
Q2 		$193K Buy
2,481
+325
+15% +$31.2K ﹤0.01% 5271
2020
Q1 		$220K Sell
2,156
-586
-21% -$61.6K ﹤0.01% 5021
2019
Q4 		$302K Buy
2,742
+458
+20% +$47.2K ﹤0.01% 5358
2019
Q3 		$207K Buy
2,284
+781
+52% +$78.9K ﹤0.01% 5650
2019
Q2 		$171K Buy
1,503
+486
+48% +$53.6K ﹤0.01% 5717
2019
Q1 		$115K Buy
1,017
+753
+285% +$78.3K ﹤0.01% 5807
2018
Q4 		$23K Buy
+264
New +$31.9K ﹤0.01% 6454

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America's STRO Position: Q1 2026 in Review

Bank of America increased its Sutro Biopharma (STRO) stake by 348% in Q1 2026, buying an estimated $265K and bringing the position to 18,873 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #4933.

Bank of America first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.2M in Q1 2022. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Bank of America held 18,873 shares of Sutro Biopharma worth $470K as of Q1 2026.
  • Bank of America bought 14,661 Sutro Biopharma shares in Q1 2026, an estimated $265K.
  • Sutro Biopharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4933 holding.
  • Bank of America first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • Bank of America's Sutro Biopharma position peaked at $2.2M in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.